Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

SGMO Sangamo Therapeutics Inc

Price (delayed)

$0.5269

Market cap

$122.86M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.39

Enterprise value

$121.05M

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, cell therapy, and genome engineering.

Highlights
The EPS has surged by 79% year-on-year and by 20% since the previous quarter
Sangamo Therapeutics's net income has surged by 76% YoY and by 19% QoQ
The equity has shrunk by 91% YoY and by 78% QoQ
The quick ratio has dropped by 60% year-on-year and by 43% since the previous quarter

Key stats

What are the main financial stats of SGMO
Market
Shares outstanding
233.17M
Market cap
$122.86M
Enterprise value
$121.05M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
24.13
Price to sales (P/S)
1.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.9
Earnings
Revenue
$63.76M
Gross profit
$63.76M
Operating income
-$82.07M
Net income
-$79.45M
EBIT
-$79.6M
EBITDA
-$70.84M
Free cash flow
-$44.89M
Per share
EPS
-$0.39
EPS diluted
-$0.4
Free cash flow per share
-$0.2
Book value per share
$0.02
Revenue per share
$0.29
TBVPS
$0.39
Balance sheet
Total assets
$86.17M
Total liabilities
$81.26M
Debt
$24.88M
Equity
$4.91M
Working capital
-$11.97M
Liquidity
Debt to equity
5.07
Current ratio
0.76
Quick ratio
0.55
Net debt/EBITDA
0.03
Margins
EBITDA margin
-111.1%
Gross margin
100%
Net margin
-124.6%
Operating margin
-128.7%
Efficiency
Return on assets
-82.4%
Return on equity
-356.8%
Return on invested capital
-173.1%
Return on capital employed
-217.4%
Return on sales
-124.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SGMO stock price

How has the Sangamo Therapeutics stock price performed over time
Intraday
7.09%
1 week
13.31%
1 month
-13.91%
1 year
-10.95%
YTD
-48.34%
QTD
-19.66%

Financial performance

How have Sangamo Therapeutics's revenue and profit performed over time
Revenue
$63.76M
Gross profit
$63.76M
Operating income
-$82.07M
Net income
-$79.45M
Gross margin
100%
Net margin
-124.6%
SGMO's net margin has soared by 93% YoY and by 26% QoQ
SGMO's operating margin has surged by 93% year-on-year and by 28% since the previous quarter
The operating income has soared by 76% YoY and by 21% from the previous quarter
Sangamo Therapeutics's net income has surged by 76% YoY and by 19% QoQ

Price vs fundamentals

How does SGMO's price correlate with its fundamentals

Growth

What is Sangamo Therapeutics's growth rate over time

Valuation

What is Sangamo Therapeutics stock price valuation
P/E
N/A
P/B
24.13
P/S
1.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.9
The EPS has surged by 79% year-on-year and by 20% since the previous quarter
The equity has shrunk by 91% YoY and by 78% QoQ
The price to book (P/B) is 91% higher than the last 4 quarters average of 11.8
The stock's P/S is 75% below its 5-year quarterly average of 6.8 and 55% below its last 4 quarters average of 3.8
The revenue is up by 10% since the previous quarter

Efficiency

How efficient is Sangamo Therapeutics business performance
The return on sales has surged by 93% year-on-year and by 26% since the previous quarter
The company's return on assets rose by 47% YoY and by 9% QoQ
The ROE has contracted by 38% YoY and by 30% from the previous quarter
Sangamo Therapeutics's return on invested capital has increased by 28% YoY and by 6% QoQ

Dividends

What is SGMO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SGMO.

Financial health

How did Sangamo Therapeutics financials performed over time
SGMO's total assets is 6% greater than its total liabilities
The quick ratio has dropped by 60% year-on-year and by 43% since the previous quarter
The company's current ratio has shrunk by 56% YoY and by 33% QoQ
The equity has shrunk by 91% YoY and by 78% QoQ
SGMO's debt is down by 19% YoY and by 5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.